Neurocrine Biosciences reported that valbenazine (Ingrezza) failed to meet its primary endpoint in the Phase 3 KINECT‑DCP trial for dyskinetic cerebral palsy. The company issued an update acknowledging the negative readout and will review the data with regulators and investigators. The development adds to recent clinical disappointments for the company. Neurocrine said it will analyze subgroup and safety data to determine next steps; the setback could reshape development priorities and investor expectations. Valbenazine’s broader neurology portfolio and commercial performance in other indications will inform management’s strategic response.